GS: 4.5% | Goldman Sachs shares are trading higher after the company reported better-than-expected Q1 EPS and revenues.

LGVN: 82% | Longeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B In Mild Alzheimer's Disease Accepted For Featured Research Session Oral Presentation At 2024 AAIC

ONVO: 65% | Organovo Announces Phase 2 Results For FXR314; Says 'Study subjects receiving FXR314 achieved statistically significant reduction in liver fat content from baseline'